An Investigational Scan (rhPSMA-7.3 PET/CT) for Detecting Biochemically Recurrent Prostate Cancer, ENLIGHTEN Trial
Recruiting · Early phase 1 · NCT06813898
Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
At a glance
- Research payments reported, 2025
- $50,658
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 27
About the trial
- Sponsor
- Northwestern University (with National Cancer Institute (NCI))
- Tested
- Computed Tomography (procedure), Electronic Health Record Review (other), Flotufolastat F-18 Gallium (drug), Positron Emission Tomography (procedure)
- Dates
- Started 2025-04-11; completion 2032-02-01
- Results posted
- Not yet
This phase II trial evaluates an imaging technique (rhPSMA-7.3 positron emission tomography \[PET\]/computed tomography \[CT\]) for detecting prostate cancer in patients who have increasing prostate-specific antigen levels following prior treatment (biochemical recurrence) but who were prostate specific membrane antigen negative on their most recent PET scan. Contrast agents like rhPSMA-7.3 (also called POSLUMA) circulate in the blood until they find their intended target. Once they are taken up by the target tumor cells, they can be visualized using PET/CT cameras. A PET scan is a procedure in which a small amount of radioactive tracer (in this case rhPSMA-7.3) is injected into a vein, a…
From ClinicalTrials.gov, last updated 2026-07-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Blue Earth Diagnostics reported $50,658 in research payments for this study in 2025 (10 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Northwestern University $50,658
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.